Literature DB >> 20390375

Gastric MALT lymphoma and grade II obesity: gastric bypass surgery as a therapeutic option.

Ricardo Helman1, Priscila Pereira dos Santos Teixeira, Carlos José Lazzarini Mendes, Thomas Szegö, Nelson Hamerschlak, Nelson Hamershlak.   

Abstract

Mucosa-associated lymphoid tissue (MALT) is the most common extranodal lymphoma, with one third of the cases occurring in the stomach. Surgical treatment is a possible option. This case report describes an obese woman (body mass index 46 kg/m2) seeking bariatric surgery, with elevated serum cholesterol and uric acid, negative for Helicobacter pylori but with a positive biopsy for MALT (immunohistochemistry), stage IA. She was submitted to a Roux-en-Y gastric bypass and gastric resection. Two months later, she had lost 20 kg and the MALT lymphoma was in complete remission.

Entities:  

Mesh:

Year:  2011        PMID: 20390375     DOI: 10.1007/s11695-010-0122-2

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  8 in total

1.  Utility of surgical resection with or without radiation therapy in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma.

Authors:  Pier Luigi Zinzani; Monica Tani; Enza Barbieri; Vittorio Stefoni; Lapo Alinari; Michele Baccarani
Journal:  Haematologica       Date:  2003-07       Impact factor: 9.941

2.  Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma.

Authors:  Agustín Avilés; Natividad Neri; M Jesús Nambo; Judith Huerta-Guzman; Sergio Cleto
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Intraoperative finding of a gastric lymphoma during gastric bypass surgery.

Authors:  Bernabé Matías Quesada; Hernán Eduardo Roff; Luis Tomás Chiappetta Porras
Journal:  Obes Surg       Date:  2007-06       Impact factor: 4.129

4.  Flexible endoscopy in the management of patients undergoing Roux-en-Y gastric bypass.

Authors:  Bruce Schirmer; Cengiz Erenoglu; Anna Miller
Journal:  Obes Surg       Date:  2002-10       Impact factor: 4.129

5.  Surgery does not adversely affect survival in primary gastrointestinal lymphoma.

Authors:  Michael C Cheung; Nadine Housri; Michael P Ogilvie; Juan E Sola; Leonidas G Koniaris
Journal:  J Surg Oncol       Date:  2009-07-01       Impact factor: 3.454

6.  Long-term follow-up of gastrectomized patients with mucosa-associated lymphoid tissue lymphoma: need for a revisit of surgical treatment.

Authors:  Sung-Hsin Kuo; Li-Tzong Chen; Ming-Shiang Wu; Chung-Wu Lin; Kun-Huei Yeh; Kuan-Ting Kuo; Pei-Yen Yeh; Yi-Shin Tzeng; Hsiu-Po Wang; Ping-Ning Hsu; Jaw-Town Lin; Ann-Lii Cheng
Journal:  Ann Surg       Date:  2008-02       Impact factor: 12.969

7.  Value of preoperative upper endoscopy in patients undergoing laparoscopic gastric bypass.

Authors:  Tallal M Zeni; Constantine T Frantzides; Claudius Mahr; E Woody Denham; Mick Meiselman; Michael J Goldberg; Susannah Spiess; Randall E Brand
Journal:  Obes Surg       Date:  2006-02       Impact factor: 4.129

8.  Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.

Authors:  Mei-Kim Ang; Siew Wan Hee; Richard Quek; Swee Peng Yap; Susan Loong; Leonard Tan; Miriam Tao; Soon Thye Lim
Journal:  Ann Hematol       Date:  2008-09-07       Impact factor: 3.673

  8 in total
  3 in total

1.  Should We Inspect Small Intestine During Laparoscopic Bariatric Surgery?

Authors:  Ivan Kruljac; Gorana Mirošević; Miroslav Bekavac Bešlin
Journal:  Obes Surg       Date:  2017-05       Impact factor: 4.129

Review 2.  Benign, premalignant, and malignant lesions encountered in bariatric surgery.

Authors:  Rao S Raghavendra; Dr Kini
Journal:  JSLS       Date:  2012 Jul-Sep       Impact factor: 2.172

3.  An Incidental Finding of Gastric Mucosa-Associated Lymphoma (MALToma) in a Sleeve Gastrectomy with Literature Review.

Authors:  Brenda Mai; Michaelangelo Friscia; Pamela Younes; Jaiyeola Thomas-Ogunniyi; Lei Chen
Journal:  Case Rep Hematol       Date:  2020-12-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.